Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib

BACKGROUND: Objective response of advanced adrenocortical carcinoma (ACC) to mitotane and cytotoxic chemotherapy regimen is only ~20% and early tumor progression is frequent. Previous clinical trials with oral multikinase inhibitors were negative, which has been attributed in part to inadvertent dru...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Endocrinol Metab
Prif Awduron: Kroiss, Matthias, Megerle, Felix, Kurlbaum, Max, Zimmermann, Sebastian, Wendler, Julia, Jimenez, Camilo, Lapa, Constantin, Quinkler, Marcus, Scherf-Clavel, Oliver, Habra, Mouhammed Amir, Fassnacht, Martin
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2020
Pynciau:
Clinical Research Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8204945/
https://ncbi.nlm.nih.gov/pubmed/31900481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/clinem/dgz318
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg